tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2022 Jul 6.
doi: 10.1080/14760584.2022.2099380. Online ahead of print.
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine
Kriangkrai Tawinprai[SUP] 1 [/SUP], Taweegrit Siripongboonsitti[SUP] 1 [/SUP], Thachanun Porntharukchareon[SUP] 1 [/SUP], Kasiruck Wittayasak[SUP] 2 [/SUP], Nawarat Thonwirak[SUP] 2 [/SUP], Kamonwan Soonklang[SUP] 2 [/SUP], Gaidganok Sornsamdang[SUP] 3 [/SUP], Chirayu Auewarakul[SUP] 4 [/SUP], Nithi Mahanonda[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Immunogenicity after the CoronaVac vaccine remains uncertain, especially regarding infections with the coronavirus variants of concern and waning immunity.
Methods: This was a single-center, open-label clinical trial designed to assess the immunogenicity and safety of BBIBP-CorV, AZD1222, or BNT162b2 as the third vaccination. The key eligible criteria were individuals at least 18 years old who were fully vaccinated with two doses of CoronaVac vaccine for 2-4 months. The primary endpoint was the ratio of the geometric mean concentration (GMC) of the total anti-receptor binding domain (RBD) antibody post-vaccination compared with that pre-vaccination. The secondary endpoint was reactogenicity within 7 days.
Results: Forty-one participants received AZD1222, 40 received BBIBP-CorV, and 40 received BNT162b2. The GMC of anti-RBD antibody at 2 weeks post-vaccination was 31,138.67 binding antibody units (BAU)/mL for BNT162b2, 6,412.10 BAU/mL for AZD1222, and 1,092.7 BAU/mL for BBIBP-CorV. Compared with pre-vaccination, the ratio of anti-RBD concentration was 690.24 for BNT162b2, 130.02 for AZD1222, and 17.79 for BBIBP-CorV. No potentially life-threatening adverse reaction were observed within 7 days.
Conclusion: A third vaccination with the heterologous vaccine, BBIBP-CorV, AZD1222, or BNT162b2, can elicit a robust immune response, without serious adverse events in participants fully vaccinated with the CoronaVac vaccine.
Keywords: AZD1222; BBIBP-CorV; BNT162b2; ChAdOx1; booster dose; immunogenicity; reactogenicity; third dose.
. 2022 Jul 6.
doi: 10.1080/14760584.2022.2099380. Online ahead of print.
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine
Kriangkrai Tawinprai[SUP] 1 [/SUP], Taweegrit Siripongboonsitti[SUP] 1 [/SUP], Thachanun Porntharukchareon[SUP] 1 [/SUP], Kasiruck Wittayasak[SUP] 2 [/SUP], Nawarat Thonwirak[SUP] 2 [/SUP], Kamonwan Soonklang[SUP] 2 [/SUP], Gaidganok Sornsamdang[SUP] 3 [/SUP], Chirayu Auewarakul[SUP] 4 [/SUP], Nithi Mahanonda[SUP] 1 [/SUP]
Affiliations
- PMID: 35792752
- DOI: 10.1080/14760584.2022.2099380
Abstract
Introduction: Immunogenicity after the CoronaVac vaccine remains uncertain, especially regarding infections with the coronavirus variants of concern and waning immunity.
Methods: This was a single-center, open-label clinical trial designed to assess the immunogenicity and safety of BBIBP-CorV, AZD1222, or BNT162b2 as the third vaccination. The key eligible criteria were individuals at least 18 years old who were fully vaccinated with two doses of CoronaVac vaccine for 2-4 months. The primary endpoint was the ratio of the geometric mean concentration (GMC) of the total anti-receptor binding domain (RBD) antibody post-vaccination compared with that pre-vaccination. The secondary endpoint was reactogenicity within 7 days.
Results: Forty-one participants received AZD1222, 40 received BBIBP-CorV, and 40 received BNT162b2. The GMC of anti-RBD antibody at 2 weeks post-vaccination was 31,138.67 binding antibody units (BAU)/mL for BNT162b2, 6,412.10 BAU/mL for AZD1222, and 1,092.7 BAU/mL for BBIBP-CorV. Compared with pre-vaccination, the ratio of anti-RBD concentration was 690.24 for BNT162b2, 130.02 for AZD1222, and 17.79 for BBIBP-CorV. No potentially life-threatening adverse reaction were observed within 7 days.
Conclusion: A third vaccination with the heterologous vaccine, BBIBP-CorV, AZD1222, or BNT162b2, can elicit a robust immune response, without serious adverse events in participants fully vaccinated with the CoronaVac vaccine.
Keywords: AZD1222; BBIBP-CorV; BNT162b2; ChAdOx1; booster dose; immunogenicity; reactogenicity; third dose.